Entrada Therapeutics
Entrada Therapeutics is a pioneering biopharmaceutical company focused on developing genetic medicines targeting previously inaccessible intracellular targets. The company is dedicated to transforming patient lives through innovative therapies for neuromuscular and inherited retinal diseases, among others.
Headquarters
Boston, Massachusetts, United States
Company Size
51-200 employees
Founded
2016
Entrada Therapeutics is a biotechnology company focused on enabling intracellular therapeutics by solving the problem of getting large molecules into cells to reach intracellular targets. They develop proprietary delivery technologies intended to expand access to previously “undruggable” intracellular targets and transform treatment options for devastating genetic and other diseases. Entrada advances its own therapeutic programs and collaborates with partners to translate its platform into clinically meaningful medicines.
Entrada Therapeutics (NASDAQ:TRDA) Hits New 1-Year High - Time to Buy?
2 days ago
Earnings Preview: Entrada Therapeutics, Inc. (TRDA) Q4 Earnings Expected to Decline
3 weeks ago
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA), Kymera Therapeutics (KYMR) and Argenx Se (ARGX)
2 weeks ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Entrada Therapeutics.
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Misses Revenue Estimates
Nov 6, 2025
VP, Program Team Leader
Dyne Therapeutics
Associate Director, Clinical Quality Assurance
Dyne Therapeutics
Senior Scientist I, Drug Product Development
AbbVie
Genetic Counsellor
University Health Network
Scientist I/II, Pre-Clinical
Lexeo Therapeutics
Principal Engineer, Technical Development
Dyne Therapeutics